Also in This Issue


Biopharmaceutical Manufacturing Goes Mainstream

With biologics, the maxim is “process is the product,” and suppliers are meeting the technologies demanded by developers with an equal amount of innovation.


The Road to Biologics’ Continued Success

In a short period of time, biopharmaceuticals have had a tremendous impact on both the pharma industry and the lives of countless patients.


Biologics: Driving Force in Pharma

Biologics actually accounted for six of the top eight drugs by revenues in 2016.

Process Analytical Technology

Making Real-Time Process Analytical Technology In Biomanufacturing A Reality

Automated, aseptic sampling and analysis is a prerequisite for making real-time Process Analytical Technology (PAT) in biomanufacturing a commercial reality.

Drug Discovery

Disease-In-A-Dish: Leveraging in vitro Human Models to Advance Drug Discovery

A personalized approach to the generation of therapeutics is gaining greater traction not only with medical personnel, but also with the patient.

Quality by Design

Speeding Development and Reducing Costs with Analytical Quality by Design

Applying Quality by Design (QbD) principles to analytical method development leads to many benefits.


Implications of Serialization for the U.S. Pharma Industry

New requirements under the U.S. Drug Supply Chain Security Act (DSCSA) have been set for pharmaceutical manufacturers.


Serialization: The First Steps In Sales Unit Traceability and Data Management

While initially driven by regulations, the impacts of serialization will be far-reaching.


Supporting the Tech Transfer Continuum for Cell & Gene Therapies

Organizations that can support the continuum of tech transfer projects will be best positioned to meet the expanding needs of the marketplace.


Propagating a Full Spectrum of Services for ADC Development and Manufacture

The development and manufacture of antibody-drug conjugates (ADCs) requires expertise in both biological drug substance and API technologies.


Moving Quality to the Forefront Brings Measurable Results

Quality initiatives are imperative in the pharmaceutical industry, but not all quality systems are equal.


Making Strides: Biologics Push Forward

Biologics are no longer seen as the ‘next big thing’ in drug development; they are now a mainstay in many pipelines.

Clinical Trials Find a Device for Growth

Technology developments and a growing population are driving growth in the clinical trials market.

The Search for Alternative Delivery Methods Continues

While biologic drugs offer numerous advantages, the need to administer them parenterally is a significant limitation.


From Blobs to Hearts: Understanding the 3D Bioprinting Revolution

Additive manufacturing (AM), commonly referred to as ‘3D printing,’ is a revolutionary technology that seems to bleed across disciplines.


Small Molecule Injectable Manufacturing: Challenges and Complexities

Despite the growth of biologic drugs, medicines based on small molecules remain important in the treatment of all types of diseases.


Building a One-Stop Shop CDMO for Biopharmaceuticals

There are few true one-stop shop organizations providing support to pharma companies developing biosimilars and branded biologics.

Drug Delivery

The People’s Choice: Premeasured Single Dosage Forms

Taking medication as intended is an issue for many patients — single unit packaging is a solution for better FDA and patient compliance.


Design of Complex Biopharmaceutical Facilities: Considering Options and Alternatives

The movement of next-generation drug products toward commercialization is driving the need for new and different technologies and facilities.


Designing Flexibility for Added Value

Biopharmaceutical facilities today rely on a wide range of equipment and processes that require a high level of flexibility.


Fit Biopharmaceutical Facilities: A Predictive Maintenance Approach

It is essential that both mature and newer existing facilities manage the aging process.

Oral Solid Dosage

Nice Symposium Oral Solid Dose 2017: Bringing the Supply Chain Together to Tackle Development Challenges

The first-ever “Nice Symposium,” hosted by That’s Nice, brought together a diverse range of service and technology providers and their customers.


Q: If You Could Have One Piece of Biologic Manufacturing Equipment Improved, What Would It Be and Why?

Improving bioreactor and cell retention setup used in perfusion processes could be a major improvement area for biologic manufacturers.


Q: How is Growth in the Biosimilars Market Impacting the Development of New Biologics Manufacturing Equipment Technologies?

Biosimilar market growth is heightening the pressure to improve cost and quality.


Q: Has Downstream Processing Technology Caught up with the Significantly Higher Titers Coming Out of the Current Upstream Process? If No, What Issues Remain?

Yes, downstream technology development is advancing to accommodate higher titers via multiple chromatography approaches.


Q: What is the Most Significant Recent Advancement in Downstream Bioprocessing Technology? Why is it so Important?

Recent advancements in continuous chromatography and SPTFF are all contributing to significant improvements across the complete process.

Issue Q3 2020

The Outsourcing Issue

View Issue »
Issue #3 | Volume #6 | Q3 2020
Issue Q2 2020

The Next-Generation Issue

View Issue »
Issue #2 | Volume #6 | Q2 2020
Issue Q1 2020

The Executive Issue

View Issue »
Issue #1 | Volume #6 | Q1 2020
Issue Q4 2019

The Breakthrough Issue

View Issue »
Issue #4 | Volume #5 | Q4 2019